2018
Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response
Warsinske H, Rao A, Moreira F, Santos P, Liu A, Scott M, Malherbe S, Ronacher K, Walzl G, Winter J, Sweeney T, Croda J, Andrews J, Khatri P. Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response. JAMA Network Open 2018, 1: e183779. PMID: 30646264, PMCID: PMC6324428, DOI: 10.1001/jamanetworkopen.2018.3779.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntitubercular AgentsBrazilChildCohort StudiesDisease ProgressionFemaleGenes, BacterialGenetic MarkersHumansLatent TuberculosisMaleMiddle AgedMolecular TypingMycobacterium tuberculosisReal-Time Polymerase Chain ReactionReproducibility of ResultsRNA, BacterialSeverity of Illness IndexTuberculosisYoung AdultConceptsTB scoreAdolescent cohort studyNegative predictive valueTreatment responseTB diseaseCohort studyTuberculosis infectionTriage testPositron emission tomography-computed tomography scanPredictive valueLatent M tuberculosis infectionLatent Mycobacterium tuberculosis infectionPrimary health care clinicsHigh negative predictive valueCulture-positive adultsM tuberculosis infectionWhole bloodMycobacterium tuberculosis infectionEnd of treatmentHealth care clinicsCase-control studyIndependent prospective cohortsDiagnosis of tuberculosisSlower treatment responseCase-control cohort
2012
Modeling the Dynamic Relationship Between HIV and the Risk of Drug-Resistant Tuberculosis
Sergeev R, Colijn C, Murray M, Cohen T. Modeling the Dynamic Relationship Between HIV and the Risk of Drug-Resistant Tuberculosis. Science Translational Medicine 2012, 4: 135ra67. PMID: 22623743, PMCID: PMC3387814, DOI: 10.1126/scitranslmed.3003815.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBDrug-resistant tuberculosisDrug-resistant TBHIV-seropositive individualsHIV statusTB patientsLatent Mycobacterium tuberculosis infectionIndividual HIV statusIncident HIV infectionMultidrug-resistant tuberculosisMycobacterium tuberculosis infectionEffects of HIVCross-sectional studyDrug-resistant formsRise of HIVIndividual-level associationsAcquisition of resistanceAverage CD4HIV infectionResistance-conferring mutationsTB controlTuberculosis infectionResistant tuberculosisTB drugsHIV epidemic
2006
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis coinfected populations
Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis coinfected populations. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 7042-7047. PMID: 16632605, PMCID: PMC1459015, DOI: 10.1073/pnas.0600349103.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyDrug-resistant TBCommunity-wide isoniazid preventive therapyPreventive therapyTuberculosis infectionTB controlLatent Mycobacterium tuberculosis infectionLatent tuberculosis infectionProportion of patientsMycobacterium tuberculosis infectionIncidence of TBTuberculosis case notificationCommunity-wide implementationEmergence of HIVCommunity-wide strategiesHIV-tuberculosisTB-HIVCoinfected individualsTB epidemicCase notificationTreatment policyHIVTherapyInfectionTB
2001
Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis
Sadaphal P, Astemborski J, Graham N, Sheely L, Bonds M, Madison A, Vlahov D, Thomas D, Sterling T. Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis. Clinical Infectious Diseases 2001, 33: 1687-1691. PMID: 11641824, PMCID: PMC2650436, DOI: 10.1086/323896.Peer-Reviewed Original ResearchConceptsHepatitis C virusInjection drug usersTuberculosis infectionValue elevationDrug usersCurrent injection drug useLatent Mycobacterium tuberculosis infectionHepatitis C virus infectionHepatitis B surface antigenLow HCV prevalenceC virus infectionIsoniazid preventive therapyInjection drug useM. tuberculosis infectionMycobacterium tuberculosis infectionHIV-1 infectionHuman immunodeficiency virusB surface antigenConcurrent alcohol useDrug discontinuationHCV prevalencePreventive therapyImmunodeficiency virusProspective studyTransaminase values
1996
The Effect of Latent Mycobacterium tuberculosis Infection on Human Immunodeficiency Virus (HIV) Disease Progression and HIV RNA Load among Injecting Drug Users
Manoff S, Farzadegan H, Muñoz A, Astemborski J, Vlahov D, Rizzo R, Solomon L, Graham N. The Effect of Latent Mycobacterium tuberculosis Infection on Human Immunodeficiency Virus (HIV) Disease Progression and HIV RNA Load among Injecting Drug Users. The Journal Of Infectious Diseases 1996, 174: 299-308. PMID: 8699059, DOI: 10.1093/infdis/174.2.299.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) disease progressionLatent Mycobacterium tuberculosis infectionMycobacterium tuberculosis infectionTuberculosis infectionSkin testingDisease progressionDrug usersLatent M. tuberculosis infectionTuberculin positive casesTuberculin-negative controlsTuberculin-negative personsCD4 cell countCohort of HIVHIV RNA loadCD4 cell declineM. tuberculosis infectionTuberculin skin testingInjecting Drug UsersBaseline immune functionHIV concentrationHIV RNAActive tuberculosisHIV burdenHIV progressionRNA load
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply